This Week in Psychedelics - 6.19.20

Cannabis

• Louisiana Governor Signs Medical Marijuana Expansion Into Law (Marijuana Moment)

• Pennsylvania: Supreme Court Rules That Medical Cannabis Use Is Permissible While on Probation (NORML)

• New Jersey Assembly Approves Marijuana Decriminalization Bill Ahead Of Legalization Referendum (Marijuana Moment)

• Switzerland releases details on recreational marijuana experiment, but full legalization likely years away (Marijuana Business Daily)

• Nevada Pardons More Than 15,000 People With Marijuana Convictions Under Governor’s Resolution (Marijuana Moment)

• Nebraskans hustle to get medical legalization on ballot, with July 3 deadline (Leafly)

• Science Reveals The Cannabis Industry’s Greatest Lie: You’re Buying Weed Wrong (And So Is Everyone Else) (Forbes)

• Ohio Marijuana Activists Plan Supreme Court Appeal After Federal Judges Deny Electronic Signature Case (Marijuana Moment)

• Using cannabis during pregnancy could be bad news for your baby: new research (The Conversation)

• Library Of Congress Highlights Racist News Coverage Used To Justify Criminalizing Marijuana A Century Ago (Marijuana Moment)

• Patients Who Use Medical Cannabis Report Being Happier and Healthier Than Those Who Don’t (Grit Daily News)

• Fed report urges doctors to treat cannabis users as drug addicts (Leafly)

• Colorado Governor Could Issue Marijuana Pardons Under Social Equity Bill Lawmakers Sent To His Desk (Marijuana Moment)

• Cannabis Can Increase Intimacy and Reduce Anxiety During Sex, New Study Finds (MERRY JANE)

• CDC Flooded With Comments On Marijuana And Kratom As Alternative Painkillers Ahead Of Deadline (Marijuana Moment)

• These 3 Marijuana Nonprofits Are Offering Real Responses To The Pandemic And Racial Injustice (Green Entrepreneur)

• A Founder Looks at 50: The Important Role of Medical Experts in Support of Legalization (NORML)

• Lawmakers Push USDA To Let Hemp Farmers Access Coronavirus Relief Funds (Marijuana Moment)

• Why the Cannabis Sector May be Turning a New Leaf (Investopedia)

Magic Mushrooms

• Combining therapy with the psychedelic drug psilocybin results in large reductions in anxiety and depression (PsyPost)

• Colorado Activists Likely To Pursue 2022 Psilocybin Ballot Measure After Poll Shows Support (Marijuana Moment)

• Numinus receives Health Canada OK for mushrooms research (PressReader)

• Palliative Canadians endure punishing waits while Health Minister delays approval of Psilocybin mushrooms; TheraPsil expands effort to Ontario (Globe Newswire)

• A Deep Dive Inside Oregon’s Path to Legalizing Psilocybin Therapy (DoubleBlind)

• Life Sciences Firm Expands Collaboration Efforts with Major US University to Develop Psilocybin-Based Medicines (StreetWise Reports)

• New Wave Holdings Corp- Launching the first publicly-traded Psilocybin-growing operation (Value the Markets)

• Cannabis Company Eyes Medicinal Magic of Mushrooms (Real Money)

• Psilocybin to Treat Anxiety and Depression in Cancer Patients (Psychedelic Science Review)

• Cute as Children, but Not Handsome as Adults: María Sabina, Life Magazine, and Cold War Propaganda (Chacruna)

DMT

• MindMed To Evaluate Ayahuasca's Active Ingredient DMT In Phase 1 Clinical Trial Collaboration (BioSpace)

• NeonMind Files Patent Application for Therapeutic Use of DMT (Yahoo! Finance)

Ayahuasca

• Is Ayahuasca Possibly Less than Five Hundred Years Old? (Chacruna)

Iboga

• Could ibogaine offer a revolutionary long-term solution to addiction? (Health Europa)

Synthetic Cannabinoids

• New K2 Compound in Canadian Heroin Supply Amid Surging Fatal ODs (Filter)

Nitrous Oxide

• Nitrous oxide use among young people is increasing in lockdown because it’s cheap and accessible (iNews)

Ketamine

• Why People are Using Ketamine Nasal Spray to Party (DoubleBlind)

• High Doses of Ketamine Can Temporarily Shut Down the Brain, Study Finds (MERRY JANE)

• Champignon’s Dr. Mcintyre / Canadian Rapid Treatment Centre of Excellence (CRTCE) Published in Two Peer Reviewed Study Journals (Globe Newswire)

Miscellaneous

• UNC to Receive $26.9M from DARPA to Develop Psychiatric Medicines (Psychedelic Science Review)

• Microsoft reportedly tried to sell facial recognition tech to the DEA (Engadget)

• Mira X Acquisition Corp. Announces Proposed Qualifying Transaction with Field Trip Psychedelics Inc. (Yahoo! Finance)

• Fixing American policing also requires an end to the war on drugs (Baker Institute Blog)

• Champignon Provides Corporate Update; Announces Name Change, Rebranding and Planned Spin Out (Globe Newswire)

• CFN Enterprises Launches Premier Psychedelics Stock Index Site: PsyIndex.com (Stockhouse)

• Beyond Stigma: How Researchers May Trigger Drug Users (Filter)

• Psychedelics Quickly Creating a Potential $100 Billion Market Opportunity (Baystreet)

• New Wave Holdings Corp Appoints Dr. Dennis McKenna to Psychedelic Research Advisory Board (PR Newswire)

• Seed crystal: on the contributions of Alexander Shulgin to the science of consciousness (Medium)

• Psychedelic Medical Start-Up AWAKN Life Sciences Enters the UK Market with Dr. Ben Sessa (Yahoo! Finance)

• Mota Ventures Appoints Roger C. Clinton as Member of Advisory Board to Verrian GmbH (MarketWatch)

• L’Chaim Psilocybin: How Psychedelics are Reigniting Judaism (DoubleBlind)

• Greenstar Biosciences Signs Agreement to Acquire 100% of Eleusian Biosciences Corp. (Yahoo! Finance)

• 2nd Gen Psychedelic Drugs For Depression Can Be Safer For Older Adults (Forbes)

• ‘Canada’s first psychedelic-enhanced psychotherapy centre’ changing how we treat depression (GlobalNews)

• Don’t Get Caught in a Trip Trap; Psychedelic Lessons for this Collective Moment (Lucid News)

• How psychedelic drugs could help our veterans (9News)

• Pure Extracts: The Second Wave of Psychedelic Operators (The Deep Dive)

Think Wilder is reader-supported. If you enjoyed this week’s update, please consider helping out by becoming a patron, making a one-time donation, or sharing this post with a friend. Thank you for your support.

Disclaimer: "This Week in Psychedelics" does not censor or analyze the news links presented here. The purpose of this column is solely to catalogue how psychedelics are presented by the mass media, which includes everything from the latest scientific research to misinformation.

Announcing PsyIndex: The World's First Psychedelic Stock Index

From a press release that came out earlier this week at Stockhouse:

CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced the launch of PsyIndex.com, a free premier stock index site and research tool designed for investors, bankers, analysts, journalists and other market participants interested in following and profiting from the emerging multi-billion dollar psychedelics and mushroom industry. The PsyIndex aggregates and tracks the public markets performance of the industry together with associated private companies, breaking news, media coverage and events.

The psychedelics industry could capture a meaningful part of the $28.6 billion global antidepressant market over the coming years as research programs and clinical trials progress towards commercialized treatment solutions. Ketamine, Psilocybin, MDMA and other psychedelics could also play a leading role in treating other high profile medical conditions, including anxiety, post-traumatic stress disorder (PTSD), ADHD and addiction. Newly formed private and public companies focused on the drug development, patient interaction and ancillary segments of the industry have peaked investor interest.

---

Post Permalink

This Week in Psychedelics - 6.12.20

Cannabis

• Government announces plan to advance cannabis legalization reforms (The Times of Israel)

• Bermuda Has Officially Proposed a Framework to Legalize Adult-Use Cannabis (MERRY JANE)

• New lawsuit aims to force DEA to reschedule marijuana (Leafly)

• Effects of cannabis edibles can vary greatly based on small differences in THC dose (PsyPost)

• Kansas Medical Marijuana Bill Dies In Committee After Special Session Ends (Marijuana Moment)

• Oregon Cannabis Association Demands Portland Cannabis Tax Not Be Used on Law Enforcement (Cannabis Business Times)

• NBA Players Union Head Joins Marijuana Company As League Reportedly Suspends Drug Testing (Marijuana Moment)

• NORML Letter to NIDA: Prohibition Must Be Recognized as More Damaging than Marijuana Itself (NORML)

• Here’s how to start fixing racism in cannabis dispensaries (Leafly)

• Nevada Governor Introduces Measure To Pardon Tens Of Thousands With Marijuana Convictions (Marijuana Moment)

• South Dakota Voters Could Make Cannabis History in November (Cannabis Wire)

• Providing the Legitimacy of Cannabinoids for the Treatment of Cancer (Onco'Zine)

• Cannabis temporarily reduces severity of PTSD symptoms (News-Medical.net)

• Do Highly Potent Marijuana Concentrates Get Users More High? Not Exactly, Study Finds (Marijuana Moment)

• Ultra-low cannabis dosing: When microdosing is still too much (Leafly)

• 5 Signs of Using Cannabis Too Frequently (Psychology Today)

LSD

• Phase 2 Clinical Trial of LSD for "Suicide Headaches" Begins Treating Patients (PR Newswire)

Magic Mushrooms

• Champignon Identifies Synthetic Ketamine and Psilocybin/Psilicin Metabolite Targets; Selects Dalriada to Advance NCE IP Portfolio (Globe Newswire)

• Rapid Therapeutic Explores Treatment of Anxiety Utilizing Proprietary Delivery System for Psilocybin and CBD (Globe Newswire)

• Dog rushed to vet after it eats human poo filled with magic mushrooms at beach (Daily Star)

MDMA

• Impressive long-term benefits of MDMA for treating PTSD, study reports (New Atlas)

• Is MDMA Neurotoxic? (Spirit Pharmacist)

DMT

• I Sell DMT Vape Pens So People Can 'Break Through' at Their Own Speed (VICE)

• Beyond Ayahuasca: Therapeutic Effects of N,N-Dimethyltryptamine (DMT) (Psychedelic Science Review)

• Former UFC Champion Henry Cejudo Details DMT Experience With Mike Tyson (MMA News)

Ayahuasca

• Not All Ayahuasca is Made Equal (Psychedelics Today)

• What if a Shaman Could Solve All Your Problems, in Three Days? (The New York Times)

Iboga

• Powerful psychedelic drug ibogaine could help people kick opioid addictions (Genetic Literacy Project)

Synthetic Cannabinoids

• Drug trial planned for synthetic cannabinoid coronavirus treatment (Chicago Tribune)

Nitrous Oxide

• No laughing matter: new legislation will ban the sale of nitrous oxide (DutchNews.nl)

Ketamine

• US customs officers find ketamine smuggled inside paintings of Jesus Christ (Mixmag)

• High doses of ketamine can temporarily switch off the brain (ScienceDaily)

Miscellaneous

• How the Psychedelic Movement Can Support Black Lives Matter (DoubleBlind)

• Protests Drive DC Psychedelics Decriminalization Signatures As Activists Launch Major Mailer Campaign (Marijuana Moment)

• We can no longer ignore the potential of psychedelic drugs to treat depression (The Guardian)

• Children and Psychedelics: Using Indigenous Wisdom to Examine Western Paradigms (Chacruna)

• How the War on Drugs Enables Police Brutality Against Black People (VICE)

• Colonial Shadows in the Psychedelic Renaissance (Chacruna)

• Help Decriminalize Nature Canada Petition the Canadian Government to Decriminalize Psychedelic Plants (Psychedelic Times)

• Are deep psychedelic experiences trustable? An exchange between Ken Ring and Chris Bache (Medium)

• The Power of Psychedelic Communities, Through the Lens of an Activist POTC (Lucid News)

• What Do Psychedelic Medicine Companies Owe to the Community? (Chacruna)

• Legal Highs: The Top Legal Psychoactive Plants in the US and Canada (DoubleBlind)

• Psychedelic Leadership Community Build at Psychedelic Liberty Summit (Chacruna)

• The Psychedelic Designs of Adam Nathaniel Furman (Sam Woolfe)

• Psychedelics Seek to Emulate Cannabis' Rise to Social Acceptance (New Kerala)

• PSYC Expanding Their Global Reach To Showcase Psychedelic Industry Leaders and Pioneers (Globe Newswire)

Think Wilder is reader-supported. If you enjoyed this week’s update, please consider helping out by becoming a patron, making a one-time donation, or sharing this post with a friend. Thank you for your support.

Disclaimer: "This Week in Psychedelics" does not censor or analyze the news links presented here. The purpose of this column is solely to catalogue how psychedelics are presented by the mass media, which includes everything from the latest scientific research to misinformation.

The Effort to Decriminalize Psychedelic Plants in Canada

Wesley Thoricatha, writing for Psychedelic Times:

After the groundbreaking success of Denver’s psilocybin measure and subsequent success of Decriminalize Nature Oakland, a national and now international movement has been sparked to reform harmful drug laws and make psychedelic plants more accessible. In Canada, a new ePetition (e-2534) is gaining traction to decriminalize psychoactive plants, backed by the group Decriminalize Nature Canada.

I’ve impressed time and time again by the series of successful drug policy reforms happening in Canada over the past several years. Now there’s a Decriminalize Nature Canada campaign aiming to decriminalize psychedelic plants at the national level. This interview explains the intention behind the movement and outlines ways that supporters can help.

---

Post Permalink

Study Finds Impressive Long-Term Benefits of MDMA for Treating PTSD

Rich Haridy, writing for New Atlas:

A new study published in the journal Psychopharmacology is presenting a comprehensive look at the long-term efficacy of MDMA-assisted psychotherapy for the treatment of post-traumatic stress disorder (PTSD). The study finds not only do the substantial beneficial effects of the therapy hold strong for well over a year after completing the treatment, but patients continue to improve as time passes following the few MDMA sessions. […]

While several studies have been published outlining positive Phase 2 trial results, this new paper investigates long-term outcomes from the treatment, compiling follow-up data from six prior trials. Around 100 subjects were included in the study.

At the original end-point of the trials, 56 percent of the cohort no longer met the clinical criteria for PTSD. The long-term follow-up data revealed continued improvements in most subjects for well over a year, with 67 percent of the cohort subsequently no longer meeting the PTSD criteria. Other long-term results noted in the cohort include reductions in suicidal thoughts and clinically significant symptom improvements.

Legally treating PTSD with MDMA-assisted psychotherapy is looking more likely than ever.

---

Post Permalink